Overview

Felodipine Modified-release Tablets and Felodipine Sustained Release Tablets in Healthy Subjects Under Fasting State: Single Dose, Randomized, Open, 2-treatment，2-period，Crossover Comparative Pharmacokinetic Study

Status:
Active, not recruiting

Trial end date:
2022-12-30

Target enrollment:

Participant gender:

Summary

Felodipine Modified-release Tablets and Felodipine Sustained Release Tablets in Healthy Subjects Under Fasting State: Single Dose, Randomized, Open, 2-treatment，2-period，Crossover Comparative Pharmacokinetic Study Main research objectives: Felodipine Modified-release Tablets (strength: 5 mg) developed by Overseas Pharmaceuticals, Ltd., and Felodipine sustained release tablets (strength: 5 mg) produced by AstraZeneca AB., trade name: The pharmacokinetic parameters of the test preparation and the reference preparation in healthy subjects under fasting state were investigated and compared. Secondary research objectives: To observe the safety of test preparation and reference preparation in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Overseas Pharmaceuticals, Ltd.

Collaborator:

Guangzhou Kangqi Medical Technology Co., LTD

Treatments:

Felodipine